Artiva Biotherapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Artiva Biotherapeutics (Nasdaq: ARTV) announced that its Board Compensation Committee approved new employee inducement grants totaling 288,800 restricted stock units for 17 new employees under the company’s 2025 Inducement Plan, effective July 14, 2026, in reliance on Nasdaq Listing Rule 5635(c)(4).
The RSUs vest over four years on quarterly vesting dates of February 15, May 15, August 15 and November 15. For each employee, 25% vests on the quarterly date closest to the one-year anniversary of their start date, and the remaining units vest in 12 equal quarterly installments, subject to continued employment and applicable grant documents.
Details
News Market Reaction – ARTV
On Jul 17, the day this news came out, ARTV closed 7.96% above the previous close. Argus tracked a peak move of +7.0% during that session. Our momentum scanner recorded 10 alerts for this stock that day.
Data tracked by StockTitan Argus for the Jul 17 session.
Key Figures
- Inducement RSUs granted
- 288,800 restricted stock units
- Aggregate grants to new employees under 2025 Inducement Plan
- Employees receiving grants
- 17 new employees
- Covered by the July 14, 2026 inducement awards
- Vesting term
- 4 years
- Inducement RSU vesting period
- Initial vesting portion
- 25% of grant
- Vests on Quarterly Vesting Date closest to one-year anniversary
- Subsequent vesting schedule
- 1/12 of remaining RSUs
- Each of the following 12 Quarterly Vesting Dates
- Quarterly Vesting Dates
- February 15, May 15, August 15, November 15
- Standard vesting dates for the Inducement Grants
- Pre-headline price change
- -8.87%
- Move vs prior close on 2026-07-16 before this announcement
- 52-week trading range
- $2.0701 to $14.53
- Low and high prior to publication
Historical Context
-
Announcement of participation in H.C. Wainwright cell therapy virtual conference.
-
AlloNK data and FDA RMAT designation in refractory rheumatoid arthritis.
-
Jefferies Global Healthcare Conference fireside chat announcement.
-
Upcoming EULAR 2026 AlloNK data presentations with strong RA efficacy signals.
-
Appointment of Diego Miralles as President and Head of R&D with equity grants.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
restricted stock units financial
nasdaq listing rule 5635(c)(4) regulatory
inducement plan financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, July 17, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced that the Compensation Committee of its Board of Directors approved new employee inducement grants covering an aggregate of 288,800 restricted stock units (the “Inducement Grants”) for 17 new employees.
The Inducement Grants were granted pursuant to Artiva’s 2025 Inducement Plan (the “Inducement Plan”), and were effective July 14, 2026. The Inducement Grants will vest over four years, with vesting aligned to quarterly vesting dates of February 15, May 15, August 15 and November 15 (the “Quarterly Vesting Dates”). For each new employee,
Artiva granted the Inducement Grants as inducements material to the employees entering into employment with Artiva in accordance with Nasdaq listing Rule 5635(c)(4).
About Artiva Biotherapeutics
Artiva is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases. Artiva’s lead program, AlloNK® (also known as AB-101), is an allogeneic, off-the-shelf, non-genetically modified, cryopreserved natural killer (NK) cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity effect of monoclonal antibodies to drive B-cell depletion. Artiva is developing AlloNK in combination with anti-CD20 antibodies in autoimmune disease, with the goal of delivering auto-CAR-T-like activity through a scalable, outpatient-administered treatment regimen compatible with community rheumatology settings. AlloNK is currently being evaluated across B-dell driven autoimmune diseases, including refractory rheumatoid arthritis (RA), Sjögren disease, systemic sclerosis and myositis. Initial clinical data have demonstrated encouraging activity across multiple autoimmune indications, along with a tolerability profile supportive of outpatient administration. Artiva plans to initiate a Phase 3 registrational trial evaluating AlloNK in refractory RA in 2026.
Artiva is headquartered in San Diego, California. For more information, please visit www.artivabio.com.
Contacts
Investors
Noopur Batsha Liffick, MPH
NBL LifeSci Advisory LLC
ir@artivabio.com
Media
Jessica Yingling, Ph.D.
Little Dog Communications Inc.
jessica@litldog.com
Source: Artiva Biotherapeutics, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.